Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 15/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5955256 | 1.00 | L3MBTL1 (0.40) | L3MBTL1CTSSMEN1KMT2AALDH1A1 | |
| SCHEMBL5415817 | 1.00 | L3MBTL1 (0.40) | L3MBTL1CTSSMEN1KMT2AALDH1A1 | |
| SCHEMBL5418141 | 0.81 | POLB (0.40) | L3MBTL1CTSSMEN1KMT2AALDH1A1 | |
| SCHEMBL5955895 | 0.81 | POLB (0.40) | L3MBTL1CTSSMEN1KMT2AALDH1A1 | |
| SCHEMBL5954873 | 0.81 | POLB (0.40) | L3MBTL1CTSSMEN1KMT2AALDH1A1 | |
| Benzene SCHEMBL5954954 | 0.77 | MEN1 (0.47) | L3MBTL1MEN1KMT2AALDH1A1HPGD | |
| Cyclopropane SCHEMBL5955262 | 0.77 | MEN1 (0.41) | L3MBTL1CTSSMEN1KMT2AALDH1A1 | |
| SCHEMBL5421601 | 0.76 | FKBP1A (0.51) | CTSSMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL5955863 | 0.76 | FKBP1A (0.51) | CTSSMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL5955811 | 0.76 | FKBP1A (0.51) | CTSSMEN1KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060089357-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-04-27 | — | — | US | disclosed |
| US-7030116-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1515726-A1 | MORPHOLINE AND TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS CATHEPSIN INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| WO-2004002491-A1 | MORPHOLINE AND TETRAHYDROPYRAN DRIVATIVES AND THEIR USE AS CATHEPSIN INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| US-20030105099-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACUETICALS INC. | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105099-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | L3MBTL1 4100/4885CTSS 1/4885MEN1 4458/4885 |
| US-20060089357-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | L3MBTL1 4100/4885CTSS 1/4885MEN1 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.